Study of Suitable Schedule of Docetaxel,Anthracycline and Cyclophosphamide in Adjuvant Therapy of Beast Cancer
Status:
Unknown status
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
Anthracycline based regimens followed by a taxane (CALGB-9344 trial and NSABP-B28) or
reversed (MD Anderson Adjuvant Trial) has already accepted as adjuvant therapy for node
positive breast cancer. Also in this group of patients, data from BCIRG-001 trial had shown
that six cycles of adjuvant TAC (docetaxel, doxorubicin and cyclophosphamide) is superior to
standard FAC (5-FU, doxorubicin and cyclophosphamide ) combination in terms of both disease
free and overall survival, while associated with a higher rate of febrile neutropenia. Then
question arose whether it is better to use docetaxel and anthracycline in combination or
sequence.